Steinberg, Gregory R. http://orcid.org/0000-0001-5425-8275
Carling, David
Article History
First Online: 13 March 2019
Competing interests
: G.R.S. has received research funding from Esperion Therapeutics and Rigel Pharmaceuticals, reagents from Pfizer and Merck, and honoraria and/or consulting fees from Astra Zeneca, Eli-Lilly, Esperion Therapeutics, Novo Nordisk, Poxel, Pfizer, Merck, Rigel and Terns.
Free to read: This content has been made available to all.